General Disclaimers

The information contained herein (the “Materials”) is provided for informational and discussion purposes only and contains statements of opinion and belief. The Materials are not, and may not be relied on in any manner as, legal, tax, or investment advice. The Materials do not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor do they constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. and its affiliates and/or any investment products it advises (collectively, “RA Capital” or the “Firm”). Each recipient should make its own investigations and evaluations of RA Capital, and any investment products it advises, and should consult its own attorney, business adviser, and tax adviser as to legal, business, tax, and related matters thereof. The information contained in the Materials is not intended to be, and should not be viewed as, “investment advice” within the meaning of 29 C.F.R. §2510.3-21 or otherwise.

Any views expressed herein, unless otherwise indicated, are those of RA Capital as of the date indicated, are based on information available to RA Capital as of such date, and are subject to change, without notice, based on market and other conditions. No representation is made or assurance given that such views are correct and such views may have become unreliable for various reasons, including changes in market conditions or economic circumstances. Such views may have been formed based upon information, believed to be reliable, that was available at the time the Materials were published. Certain information contained herein concerning economic trends and/or data may be based on or derived from information provided by independent third-party sources. RA Capital believes that the sources from which such information has been obtained are reliable; however, it cannot guarantee the accuracy of such information and has not independently verified the accuracy or completeness of such information or the assumptions on which such information is based. RA Capital has no duty or obligation to update the information contained herein.

The content of the Materials neither constitutes investment advice nor offers any opinion with respect to the suitability of any security. Any references, either general or specific, to securities and/or issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, advice or recommendations to purchase, continue to hold, or sell such securities, or as an endorsement of any security or company. Certain current and prior investments may be highlighted in order to provide additional information regarding RA Capital’s investment strategy, the types of investments it pursues, and current or anticipated exit strategies. In addition, due to confidentiality restrictions, the information contained herein might not represent investments in certain companies. Accounts managed by RA Capital may invest in certain companies referenced in the Materials; however, RA Capital makes no guarantees as to the accuracy or completeness of views expressed in the Materials. Any strategies and companies referenced in the Materials may not be suitable for all investors.

As stated above, the Materials are not an offer or solicitation for the purchase or sale of any security, including any interest in RA Capital Healthcare Fund, L.P. (the “Master Fund”) or RA Capital Healthcare Fund International Ltd. (the “Offshore Fund,” and, collectively with the Master Fund, the “Fund”), and should not be construed as such. Such an offer will only be made by means of a confidential Private Placement Memorandum (the “PPM”) to be furnished to qualified investors upon request. The information contained herein is qualified in its entirety by the PPM, which contains additional information about the investment objective, terms, and conditions of an investment in the Fund, and also contains certain disclosures that are important to consider when making an investment decision regarding the Fund. In the case of any inconsistency between any information contained herein or in the Materials and the PPM, the terms of the PPM shall control.

The Materials are proprietary and confidential and may include commercially sensitive information. As such, the Materials must be kept strictly confidential and may not be copied or used for an improper purpose, reproduced, republished, or posted in whole or in part, in any form, without the prior written consent of RA Capital. The recipient of the Materials must not make any communication regarding the information contained herein, including disclosing that the Materials have been provided to such recipient, to any person other than its authorized representatives assisting in considering the information contained herein. Each recipient agrees to the foregoing and to return (or destroy upon RA Capital’s instructions) the Materials promptly upon request.

Any investment strategies discussed herein are speculative and involve a high degree of risk, including loss of capital. Investments in any products described herein and the Fund’s performance can be volatile, and investors should have the financial ability and be willing to accept such risks. An investor could lose all or a substantial amount of his or her investment. The Fund may be leveraged. Interests in the Fund are illiquid, as there is no secondary market for the Fund interests, and none is expected to develop. The Fund interests are subject to restrictions on transfer. Prior to investing in the Fund, investors should read the PPM and pay particular attention to the risk factors contained therein. Fees and expenses charged in connection with an investment in the Fund may be higher than the fees and expenses of other investment alternatives and may offset investment profits of the Fund. RA Capital has total trading authority over the Fund. The use of a single advisor applying generally similar trading programs could mean lack of diversification and, consequently, higher risk. A portion of the trades executed for the Fund may take place on foreign exchanges. It should not be assumed, and no representation is made, that past investment performance is reflective of future results. Nothing herein should be deemed to be a prediction or projection of future performance. To the extent any prior or existing investments are described, RA Capital makes no representations, and it should not be assumed, that past investment selection is necessarily reflective of future investment selection, that any performance discussed herein will be achieved or that similar investment opportunities will be available in the future or, if made, will achieve similar results.

In particular, to the extent valuation information is provided for any unrealized investments, such valuations are RA Capital’s estimates as of the date set forth in the Materials, and there can be no assurance that unrealized investments will be realized at such valuations. While RA Capital believes any valuations presented herein are reasonable, such valuations may be highly subjective, particularly for private investments, and are based on information provided by third parties and/or RA Capital’s assumptions, any or all of which might be mistaken or incomplete. Actual realized returns will depend on, among other factors, future operating results, the value of the assets and market conditions at the time of disposition, any related transaction costs, and the timing and manner or sale, all of which may differ from the assumptions on which the valuations contained herein are based. As a result of the foregoing, actual realized returns may differ materially from the valuations contained herein.

Certain information contained in this document constitutes “forward-looking statements,” which can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “anticipate,” “continue,” “expect,” “intend,” “estimate,” “project,” “believe,” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results or the actual performance of any investment may differ from those reflected or contemplated in such forward-looking statements. Prospective investors should not rely on these forward-looking statements when making an investment decision.

None of the information contained herein has been filed with the U.S. Securities and Exchange Commission, any securities administrator under any securities laws of any U.S. or non-U.S. jurisdiction, or any other U.S. or non-U.S. governmental or self-regulatory authority. No such governmental or self-regulatory authority will pass on the merits of any offering of interests by RA Capital or the adequacy of the information contained herein. Any representation to the contrary is unlawful. The interests in the Fund have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended, or qualified or registered under any applicable state, local, provincial, or other statutes, rules, or regulations. The Fund has not been, and will not be, registered as an investment company under the U.S. Investment Company Act of 1940, as amended.
How to Save $200 Billion and Cure Hepatitis C
Peter Kolchinsky 7/22/13

Wall Street is buzzing with anticipation about the first new all-oral drugs for hepatitis C approaching the market. The high rate of HCV infection and dissatisfaction with current treatments have created a potential multi-billion dollar bonanza for drug companies. It’s estimated that Gilead, the frontrunner in this race, will charge as much as $90,000 per patient. With roughly 3 million infected patients currently in the U.S., that’s about $270 billion to cure everyone.

Is this necessary? Or even advisable? Particularly in the case of hepatitis C, payers, physicians, and patients can collaborate to extract huge price concessions from pharmaceutical companies, netting more than $200 billion in savings. All they have to do is acknowledge that sometimes “good enough” is better than “best.” I’m wagering they will, and that’s why my firm, RA Capital, has invested in Achillion Pharmaceuticals, which we believe will compete quite aggressively and effectively on price once they launch their HCV therapy in 2016.

Price competition is going to play a bigger and bigger role in containing healthcare cost, and HCV treatment is one area where such competition won’t have to come at the expense of patient welfare.

An estimated 150 million people are infected with hepatitis C worldwide. All current treatment regimens require long-term, weekly interferon injections with significant side effects. Many patients can’t tolerate those or just don’t want to bother with them. Because the disease progresses slowly, patients can and do wait for years for better treatment choices. Hence the mounting anticipation for the all-oral treatments.

Clearly, being first to market will be a plus. Both Gilead and AbbVie are likely to get approvals around the same time towards the fall of 2014. Gilead’s treatment also appears to deliver the highest cure rate (about 95 percent) and will comprise just a single pill daily for eight to twelve weeks. Abbvie’s regimen has a similar cure rate but requires taking a number of pills twice a day. By 2016, several other all-oral treatments are expected to be approved, including one from Bristol-Myers Squibb and another from Achillion, a small biotech.

Analysts are buzzing about the various characteristics of the new drugs and trying to determine which company has the advantage. All of these combo drug regimens are expected to provide cure rates of 85 percent or better, but there are slight differences in their side-effect profiles, pills per day, treatment duration and cure rates. By most accounts, Gilead offers the “best” treatment and is therefore expected to both charge top dollar and win a majority market share. Its stock has more than doubled in the last year to a $90 billion valuation on high expectations for hepatitis C drug sales.

In business-as-usual mode, U.S. payers would just throw open their wallets and pay whatever it costs to provide the “best” therapy to all the patients who could benefit. But once they start receiving the bills, payers and providers may begin singing a different tune. Certainly, some patients with advanced disease will immediately require treatment with the “best” drug available. But many patients are still in the early stages of Hepatitis C and will feel no sense of urgency. With at least four competitive “good-enough” all-oral regimens on the market by 2016, payers could negotiate dramatically reduced prices, awarding the lowest bidder the privilege of selling the first line treatment. The small percent of patients who fail that regimen could then cycle onto the best and presumably most expensive one.

This approach is extremely simple and convenient for patients, compared to today’s regimens that can take up to a year and require injections with many side effects. Indeed, this is similar to the way doctors usually prescribe antibiotics, moving to the more expensive options only after the cheaper ones have been exhausted.

After all, every one of these drugs represents a huge improvement over current therapy. They are all “good enough” to cure most patients. And, assuming that the first-line drug could be negotiated down to as low as $10,000, each patient who responds to the cheapest drug (most will) would save the system as much as $80,000 compared to using the best drug first. By our calculations, the cumulative savings nationwide would be as much as $200 billion in
the U.S. alone over the next decade. Similar savings await other nations.

Certainly companies deserve to be rewarded for tremendous breakthroughs like the new hepatitis C drugs. And many on Wall Street are incredulous that drug companies will lower their prices. Indeed, large pharmaceuticals companies don’t have a strong track record of offering deep discounts even in the face of significant competition. For example, there are many drugs approved for multiple sclerosis yet the prices for these only go up each year.

But hepatitis C is a big market and a certain type of company could still do quite well charging even $10,000 per patient. The 3 million patients in the U.S. alone could net $30 billion of sales, which might be modest for Gilead shareholders but would be a windfall for a company as small as Achillion, whose market capitalization is less than 1 percent of Gilead’s valuation. So even if having Gilead, AbbVie, and Bristol-Myers on the market is not enough to spark a price war by 2015, payers will likely get a discounted offer they can’t refuse from Achillion in early 2016.

To some, the idea of using merely “good enough” drugs will seem offensive. It’s a point of pride for Americans that patients come first and doctors have the freedom to prescribe the best regardless of cost. Even if this American healthcare fantasy were true, when the most expensive route to a cure is merely more convenient than the least expensive drug regimen, are those extra billions of dollars worth it? My bet is that private and public insurers will both be taking a much closer look at scenarios like this one, cutting wherever they can reap huge savings without harming patients.

Besides, if $90,000 were offered directly to patients, what would they chose? My guess is that most would buy the cheaper drugs, get cured for less, and put the massive savings towards countless other necessities.

If only reimbursement worked that way.

Hepatitis C has proven to be surprisingly easy to cure and we will soon see multiple “good enough” drugs on the market, which makes it easy for payers and providers to negotiate down prices on behalf of patients, employers, and taxpayers. Just as oncologists have started to push back against high drug prices, others will begin taking a stance against exorbitant spending, especially for mere convenience.

After all, our definition of "best" has left us with the priciest healthcare system in the world, but not always the best outcomes. HCV treatment is one textbook example of how mindlessly sticking to our old ways will have spectacularly expensive consequences.

—Peter Kolchinsky is RA Capital’s founder, Managing Director, and Portfolio Manager.